Form 10-Q Echo Therapeutics, Inc. For: Sep 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/1/2026
- S&P 500 dips, Nasdaq higher after data shows moderate inflation rise
- Equity positioning stays overweight, but summer extremes have eased: Barclays
- Oil prices rise by about $1/bbl on stalled US-Iran talks and tight fuel markets
- Micron reports Q4 today: Why Lynx Equity sees massive upside
- Moderna: Citi says oncology optimism is priced in, cuts rating to sell
- Zimbabwe helicopter crash kills six, government spokesperson says
- Apple's iOS 27 is blocking Trade Desk ads on Safari, analyst says
- S&P 500 dips, Nasdaq higher after data shows moderate inflation rise
- Mattel names Roger Lynch as chairman and CEO, replacing Ynon Kreiz
- HPE raises networking revenue outlook, secures $1.2B Vultr order
Echo Therapeutics (ECTE) Posts Narrower Q3 Loss
November 19, 2014 5:26 PM ESTEcho Therapeutics (NASDAQ: ECTE) reported Q3 EPS of ($0.43), versus ($0.49) reported last year. Revenue for the quarter came in at $19.11 million, versus $22.56 million reported last year.
For earnings history and earnings-related data on Echo Therapeutics (ECTE) click here.
... More